FDA approves iCAD’s colon scan


The U.S. Food and Drug Administration has cleared VeraLook, iCAD’s computer-aided detection system for virtual colonoscopies, the Nashua company has announced.iCAD’s VeraLook uses sophisticated technology and algorithms to identify polyps in images produced by a virtual colonoscopy, also known as CT colonography.Suspicious polyps are highlighted on the images for physicians after initial review to flag areas that warrant further investigation.According to the company, extensive testing has shown that VeraLook "improved reader sensitivity to all colonic polyps 6mm or larger in size in a statistically significant manner and particularly for smaller, more easily missed polyps and pre-cancerous polyps which can develop into malignancies over time."iCAD also said that VeraLook also has "high standalone sensitivity" for detecting polyps, with a minimal number of false positives.Virtual colonoscopies eliminate the use of the long optical scope that is inserted into the rectum and snaked through the colon as used in traditional, or optical, colonoscopies.They also do not require the use of anesthetics, unlike traditional methods, for which patients are sedated or are unconscious.Both procedures require the same fasting and bowel-cleansing process prior to the exam.One advantage of optical colonoscopies is that if a suspicious polyp is seen during the exam, it can be removed at the time for further evaluation. With virtual colonoscopies, a concerning polyp would have to be removed during a second procedure. – CINDY KIBBE/NEW HAMPSHIRE BUSINESS REVIEW
Edit ModuleShow Tags